From Pharma Lobby to Drug Pricing Policy
How industry spending shaped Medicare negotiation rules
The pharmaceutical industry spent billions lobbying against Medicare drug price negotiation. Follow the pipeline from PhRMA and individual companies through lobbyists, campaign donations, and revolving-door hires to see how industry money influenced the final legislation.
PhRMA leads the lobbying campaign
The Pharmaceutical Research and Manufacturers of America (PhRMA) is the drug industry's most powerful trade group. It spent hundreds of millions lobbying against Medicare drug price negotiation provisions in the Inflation Reduction Act.
The largest and most influential pharmaceutical trade association in the US. Spends over $30 million per year on lobbying, making it one of the top lobbying organizations in Washington. Led opposition...
Pfizer supports the effort through its PAC
Pfizer, one of the world's largest drug companies, channeled money through its corporate PAC to members of Congress who opposed or weakened drug pricing provisions. The company had a direct financial interest in preventing government negotiation of drug prices.
Pfizer Inc. PAC donates to key committee members
Pfizer's PAC directed donations strategically to members of the House Energy and Commerce Committee and Senate Finance Committee — the two panels with jurisdiction over drug pricing legislation.
Pfizer employee political action committee. One of the largest pharma PACs, contributing to members of health and commerce committees.